Hydrochloric Acid

Hydrochloric Acid

SCHEMBL316957

C=CC(=O)OCC(NC)(NC)NC.Cl

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
TP53 P04637 3/20 0.52
HIF1A Q16665 3/20 0.52
CYP3A4 P08684 2/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TSHR P16473 7/20 0.44
THRB P10828 2/20 0.43
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3990182 0.98 ALDH1A1 (0.53) ALDH1A1TP53HIF1ACYP3A4MAPK1
Sulfuric Acid SCHEMBL8717714 0.91 ALDH1A1 (0.47) ALDH1A1TP53HIF1ACYP3A4MAPK1
SCHEMBL8976328 0.86 ALDH1A1 (0.43) ALDH1A1TP53HIF1ACYP3A4MAPK1
Dimethylamine SCHEMBL6114524 0.78 ALDH1A1 (0.53) ALDH1A1TP53HIF1ACYP3A4MAPK1
Hydrochloric Acid SCHEMBL3317335 0.75 TSHR (0.61) ALDH1A1TP53HIF1ACYP3A4MAPK1
Hydrochloric Acid SCHEMBL3308705 0.75 TSHR (0.61) ALDH1A1TP53HIF1ACYP3A4MAPK1
Hydrochloric Acid SCHEMBL3310744 0.75 TSHR (0.61) ALDH1A1TP53HIF1ACYP3A4MAPK1
Hydrochloric Acid SCHEMBL28271407 0.75 ALDH1A1 (0.55) ALDH1A1TP53HIF1ACYP3A4MAPK1
SCHEMBL5696399 0.74 ALDH1A1 (0.50) ALDH1A1TP53HIF1ACYP3A4MAPK1
SCHEMBL22799958 0.74 ALDH1A1 (0.60) ALDH1A1TP53HIF1ACYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465676-B1 FILM-FORMING COMPOSITIONS AND THEIR USES 3M INNOVATIVE PROPERTIES CO (US) 2007-08-15 EP claimed
US-5783533-A COPOLYMER CONTAINING ACRYLIC ACID TYPE GROUPS, ACRYLIC, VINYL, OR ALLYL MONOMERS WITH PENDANT AMMONIUM OR SULFONIUM GROUPS, POSSIBLY WITH POLYOXYALKYLENE ETHER SECTION, RHEOLOGY MODIFIERS COATEX S.A. (FR) 1998-07-21 US claimed
EP-0580529-B1 Process for making paper or cardboard having improved retention S N F (FR) 1996-04-17 EP claimed
CN-114514251-B Polymer dispersions and fabric conditioning compositions comprising the same 罗地亚经营管理公司 2024-06-14 CN disclosed
CN-117120588-A Fabric conditioner 联合利华知识产权控股有限公司 2023-11-24 CN disclosed
US-20210046143-A1 METHOD FOR TREATMENT OF THE HUMAN BODY BY THERAPY BY ADMINISTERING A COMPOSITION COMPRISING A PLANT EXTRACT OF THE SPECIE HEDYCHIUM CORONARIUM SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) 2021-02-18 US disclosed
CN-106459835-B Composition comprising quaternary ammonium compound, cationic polysaccharide and nonionic polysaccharide 罗地亚经营管理公司 2021-01-26 CN disclosed
CN-106414690-B Methods of using compositions comprising quaternary ammonium compounds, cationic polysaccharides, and nonionic polysaccharides 罗地亚经营管理公司 2021-01-26 CN disclosed
CN-107115326-B Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof 雷尔玛达治疗股份有限公司 2021-01-22 CN disclosed
EP-3064065-B1 ANTISEPTIC COMPOSITIONS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2020-08-12 EP disclosed
EP-3562559-A1 COMPOSITION COMPRISING A PLANT EXTRACT OF THE SPECIE HEDYCHIUM CORONARIUM, FOR USE IN A METHOD FOR TREATMENT OF THE HUMAN BODY BY THERAPY Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) 2019-11-06 EP disclosed
US-6903243-B1 Multi-layer absorbent wound dressing 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-07 US disclosed
US-20050118119-A1 Use of a compound inactivating the kinase a protein in a composition containg a cosmetically acceptable medium in order to lighten the skin SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (SEPPIC) (FR) 2005-06-02 US disclosed
EP-1465676-A1 FILM-FORMING COMPOSITIONS AND METHODS 3M Innovative Properties Company (US) 2004-10-13 EP disclosed
US-20040071642-A1 Novel topical compositions with an oily outer phase and process for their preparation SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES-SEPPIC 2004-04-15 US disclosed
WO-2003061721-A1 FILM-FORMING COMPOSITIONS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-07-31 WO disclosed
US-20030133957-A1 Topical compositions with outer phase and preparation method SOCIETE D"EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES-SEPPIC (FR) 2003-07-17 US disclosed
EP-1315527-A2 MULTI-LAYER ABSORBENT WOUND DRESSING 3M Innovative Properties Company (US) 2003-06-04 EP disclosed
WO-2002020067-A2 MULTI-LAYER ABSORBENT WOUND DRESSING 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-03-14 WO disclosed
US-5783533-A COPOLYMER CONTAINING ACRYLIC ACID TYPE GROUPS, ACRYLIC, VINYL, OR ALLYL MONOMERS WITH PENDANT AMMONIUM OR SULFONIUM GROUPS, POSSIBLY WITH POLYOXYALKYLENE ETHER SECTION, RHEOLOGY MODIFIERS COATEX S.A. (FR) 1998-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040071642-A1 Novel topical compositions with an oily outer phase and process for their preparation CUTA, TYR, ERCC5 ALDH1A1 273/4885TP53 23/4885HIF1A 1284/4885
US-20030133957-A1 Topical compositions with outer phase and preparation method CUTA, LIPA, CETP ALDH1A1 2254/4885TP53 1311/4885HIF1A 1657/4885
US-20050118119-A1 Use of a compound inactivating the kinase a protein in a composition containg a cosmetically acceptable medium in order to lighten the skin PRKACG, PRKACA, PRKACB ALDH1A1 2852/4885TP53 1547/4885HIF1A 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.